Navigation Links
TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Date:10/13/2009

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections. The alarming rise in the number of multidrug-resistant (MDR) bacterial pathogens that have emerged and spread in recent years has dramatically reduced the utility of the current arsenal of antibiotics. Two such MDR pathogens in particular have been recognized as major threats to global public health, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). TAXIS is in the process of identifying and validating lead drug candidates that target MRSA and VRE with efficacies that are superior to current standards of therapeutic care.

"The compounds under investigation have great potential to treat a broad-spectrum of emerging, drug-resistant pathogens that represent large and growing public health and biodefense threats", said Gregory Mario, TAXIS' Chief Executive Officer. "We are excited to develop these further and move them closer to the clinic." The novel antimicrobial technology was discovered at the universities by Professors Daniel S. Pilch, Ph.D. (Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School) and Edmond J. LaVoie, Ph.D. (Department of Medicinal Chemistry, Rutgers University-Ernest Mario School of Pharmacy).


'/>"/>

Contact: Gregory G. Mario
GMario@TAXISPharma.com
609-240-8463
Rutgers University
Source:Eurekalert

Page: 1

Related biology news :

1. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
2. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
3. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
4. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Bacteria from sponges make new pharmaceuticals
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not ... one of the most crucial aspects of recovery so we need to do it ... health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... sleep and find a Christmas present that could help them to manage their sleep ... ...
(Date:11/29/2016)... -- Nearly one billion matches per second with DERMALOG,s high-speed ... ... DERMALOG is Germany's largest Multi-Biometric supplier: ... (PRNewsFoto/DERMALOG Identification Systems) ... is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...
(Date:12/8/2016)... 2016 Oxford Gene ... seine Palette an anpassbaren SureSeq™ NGS-Panels mit dem ... das ein schnelles und kostengünstiges Studium der Varianten ... eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) ... kleinen Panel und ermöglicht eine individuelle Anpassung durch ...
(Date:12/8/2016)... Dec. 8, 2016  Anaconda BioMed S.L., a pre-clinical ... the next generation neuro-thrombectomy system for the treatment of ... G. Jovin, MD to join its Scientific Advisory Board ... strategic network of scientific and clinical experts to Anaconda ... the ANCD BRAIN ® to its clinical phase. ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
Breaking Biology Technology: